Continuing Education

Benefits of Probiotics in the Management of Gastrointestinal Disorders

Release Date: 
Expiration Date: 
CE Topic: 
Grant Supported: 


Marsha K. Millonig, MBA, BSPharm
President & CEO
Catalyst Enterprises, LLC
Eagan, Minnesota


Marsha K. Millonig, MBA, BSPharm, has no real or apparent conflicts of interest in relation to this program.

Susanne Batesko, RN, BSN, Michele Salernitano, the clinical reviewers, planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.



Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-11-040-H01-P
Credits: 2.0 hours (0.20 ceu)
Type of Activity: Knowledge


This accredited activity has been designed for Pharmacists.

Exam processing and other inquiries and booklet orders to:
CE Customer Service: (800) 825-4696 or


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.


The purpose of this lesson is to educate pharmacists about probiotics, the clinical data supporting the use of these agents, and the appropriate selection, dosage, and administration of probiotics for the treatment of gastrointestinal (GI) diseases.


After completing this activity, the participant should be able to:

  1. Explain the scientific rationale for the use of probiotics to maitain gastrointestinal (GI) health and for the treatment of disease, as well as the various mechanisms of action;
  2. Review background data about probiotics, as well as current clinical trial data about probiotic efficacy and safety;
  3. Differentiate between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and discuss clinical trial data investigating probiotics for the treatment of these GI disorders; and
  4. Discuss probiotic formulation distinctions and factors related to the appropriate administration of probiotics.
Your rating: None Average: 4 (1 vote)